Fifty-one patients with gonadal dysgenesis receiving estrogen progesterone replacement therapy for periods of six months to twenty years were studied. Endometrial biopsies or dilatation and curettage were obtained in forty-seven patients. One patient on diethylstilbesterol had atypical endometrial hyperplasia which progressed to adenoepidermoid carcinoma. Six patients had benign cystic hyperplasia. Endometrial abnormalities occurred in patients with a duration of estrogen therapy greater than 3-5/12 years and who received a total lifetime estrogen dose exceeding 2500 mg of conjugated estrogen or its equivalent. Five patients who developed endometrial hyperplasia had taken cyclic estrogen-progesterone therapy; the sixth took unopposed estrogen therapy.
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Total nuclear estradiol binding was measured in six patients with Turner Syndrome and nine control women. Two of the Turner patients had endometrial hyperplasia. Nuclear binding in these two subjects did not differ from that of the other patients with Turner Syndrome. Nuclear binding in the Turner patients (range 3-lOl/DPM ng DNA) was not different from that of nine control women at comparable stages of the menstrual cycle (34-429 DPM/ng DNA). Growth hormone (GH) secretion was monitored continuously over 4 hours in 23 children with IDD to investigate the hypothesis hat GH secretion evaluated in a physiologic fashion reflects the eqree of ambiant glycemia. A constant blood withdrawal system s used on ambulatory subjects who otherwise were maintained on eir usual diabetic routine. All of the subjects studied had long standing insulin dependncy and none exhibited clinical or biochemical evidence of hypolycemia during the study period. Eight normal children (NC) re similarly studied. 
** Linear regression analysis
Examination of the diurnal pattern of GH secretion revealed 10 difference in number of secretion episodes or in the ratio of swake/asleep GH secretion. Despite the normal mean ICGH, con-:iderable individual variation in GH levels in IDD was observed. In additional 13 patients with IDD, not included with these data 2ecause of hypoglycemia, also had a normal mean ICGH and comparnbly wide individual variation.
Conclusion: There is no direct relationship between GH secret. .on and the degree of hyperglycemia in IDD.
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The onset of glucose intolerance in three patients receiving oxymetholone for aplastic anemia (AA), an association not preEight patients aged 9 to 20 years with acquired AA orfanconi' f 1 to 5 mglkgld for 11 to 139 months and one patient did not equire oxymetholone. All had oral glucose tolerance tests (OGTT) ith glucose and total immunoreactive insulin (TIRI) determined t 0, 4, 1, 2, 3, and 4 hours. Seven patients had HLA analyses.
The mean glucose of the seven patients receiving oxymetholone as elevated during OGTT (p<0.001 for each sampling time). TIRI as elevated in five of these patients (pC0.05-0.001). In these ive patients basal TIRI correlated with dose (~0 . 8 9 , p<0.01) nd duration (r=0.98, p<0.001) of oxymetholone therapy. TIRI reponse areas also correlated with dose and duration of treatment r=0.83, p<0.05 and r=0.90, p<0.01, respectively). The two reaining patients were overtly diabetic siblings with 1owTIRI. he patient not receiving oxymetholone had normal OGTT and TIRI evels. In one patient OGTT was normal prior to therapy but abith idiopathic precocious puberty and precocious thclarche. We tudied 10 girls ages 29112-76/12 with rapid breast development. uring the 9 mos. to 4 yrs. of follow-up 5 girls had progressive ubertal development (group A); breast development in the other 5 group 8) either resolved or fluctuated. Two girls in group B resented with light menstrual bleeding. Clinical course could ot be predicted by the initial physical exam, serum E2 or 24h rinary estrogen excretion. The greatest E2 value (222 pg/ml) as in a 53/12 yr. girl in group B. Subsequent E2 values decreas d over 8 mos. to 26 ~g/ml. A GnRH test (2.%g/kg iv) was done uring initial evaluation of all girls. Basal serum LH values or group A (6.621.6,MASE) and B (4.1A0.6) were not significantly ifferent; basal serum FSH values for A(10.0+_2.9) were signifiantly greater than B(2.5T0.6).
In A the GnRH response in 4 irls fell within or above the normal adult range and in one girl as normal for bone age. Three girls in B had no LH or FSH reponses and 2 had low prepubertal responses. All 3 girls who ailed to respond to GnRH had intermittent leukorrhea and breas nlargement and one had normal appearing ovaries on laparo:,copy ne girl in B with a low prepubertal GnRH response had bilatera varian cysts. These observations suggest: 1) the GnRH test ma useful in predicting the clinical course of girls with isose 
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Rational and safe use of drugs includes weighing the indication of a drug versus the risk of reactions. 110 instances of drug use were analyzed in 27 neonates with 47 identified drug reactions. Birth weight, gestational age, admission age and length of hospital stay ranged from 835-3570 g, 24-41 wks, 0.5 65 days, and 0.5 -100 days respectively. To assess the accurac of drug use the depree of indication at initiation of therapy was compared to that at discharge or completion of therapy. 9 degrees (definite, presumptive but highly indicated, resuscitative, prophylactic, procedure-related, empirical, palliative, not indicated, not classified) were based on set clinical, laboratory and pharmacologic criteria. 113 of drug use was definitely indicated. Of 21 drugs initially presumed highly indicated 7 became definitely indicated, but 7 were not indicated, sugges ting overtreatment in at least 30% of presumed-indicated drugs. Adverse drug reactions were noted in many drugs not definitely indicated, suggestinp that risk may be greater than benefit. Da ta underscore the need for more careful and rational use of d r~ Indication0
Initial C(%) activity. Subsequently 4/7 CSF isr-ates were positive for 6-lactamase activity. The in vitro susceptibilities of 30 13-lacta mase ( + ) Hemophilus strains to ampicillin, chloramphenicol, cefa mandole, cefachlor, tetracycline and trimethoprim-sulfamethoxazole were evaluated using a microtiter broth dilution method. 70% of strains were resistaqt to Lamp1 of 110 ug/ml (MIC range = 4-128 ug/ml), while all were inhibited by ~1 ug/ml of chloramphenicol (MIC=0.25-1 ug/ml). Strains were highly susceptible to cefamandole (90% inhibited by 50.5 ug/ml), although only 25% of strains were inhibited by 51 11g/ml of cefachlor (MIC-1-16 pg/ml) All isolates were inhibited by [tetracycline1 of 51 ug/ml. MICs of TMP-SMZ ranged from .0037/.148-.125/2.37 u g h 1 with 75% of strains susceptible to 50.03/.59 ug/ml. The incidence of 0-lacta nase (+I Hemophilus strains in Michigan appears to be increasing These strains are highly susceptible ln vitro to chloramphenicol cefamandole and TMP-SMZ.
